Affiliation:
1. Consulting surgeon BARC Hospital.
2. Senior resident BARC Hospital.
Abstract
Drug resistance of bacteria is biggest challenge humanity is going to
face in near future. Bacteria are rapidly developing resistant to
multiple drugs and there are not many new drugs in pipeline. Infection
because of drug resistant organism is a common cause of morbidity
and mortality in intensive care unit. If acquisition of drug resistance by
microorganism progresses at this rate, that time is not very far when we
will be pushed in to preantibiotic era. We need to develop new
strategies to combat drug resistant by microorganism. We report a case
of highly drug resistant urinary tract infection caused by Klebsiella.
This strain was resistant to both Inj. Meropenem and Inj. Amikacin.
This case was successfully treated by combination of Inj. Meropenem
and Inj. Amikacin and complete resolution of infection was observed.
Reference18 articles.
1. Behzadi, P., Behzadi, E., Yazdanbod, H., Aghapour, R., Akbari Cheshmeh, M., & Salehian Omran, D. (2010). A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica, 5(2), 111–115
2. Yasin, F., Assad, S., Talpur, A. S., Zahid, M., & Malik, S. A. (2017). Combination Therapy for Multidrug-Resistant Klebsiella Pneumoniae Urinary Tract Infection. Cureus, 9(7), e1503. https://doi.org/10.7759/cureus.1503
3. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance, Johann D. D. Pitout, Patrice Nordmann, Laurent Poirel
4. Antimicrobial Agents and Chemotherapy Sep 2015, 59 (10) 5873-5884; DOI: 10.1128/AAC.01019-15
5. Nordmann P, Poirel L. 2014. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worgeldwide. Clin Microbiol Infect 20:821–830. doi:10.1111/1469-0691.12719